CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/comparative-efficacy-subq-vs-intravenous-dmts-in-alzheimers-disease/26347/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and Joh…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/dementia-on-a-spectrum-preclinical-stages-of-mci-in-ad/26339/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discu…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/markers-of-memory-pathological-biomarkers-of-clinical-mci-due-to-ad/26344/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and Joh…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/beyond-guesswork-validated-methods-for-mci-assessment-in-alzheimers-diagnosis/26342/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabba…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/inequity-and-illness-understanding-mci-disease-course-and-severity-for-racial-minorities/26341/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. M…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-the-latest-data-on-ad-disease-modifying-therapies/26345/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John …

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/precision-imaging-mris-critical-role-in-early-mci-ad-diagnosis/26343/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Har…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/future-frontiers-the-future-landscape-of-alzheimers-therapeutics/26348/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John H…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/therapeutic-insights-navigating-the-use-and-challenges-of-disease-modifying-therapies/26346/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marw…

CME credits: 1.00 Valid until: 25-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-subtle-onset-understanding-early-mci-ad-symptoms/26340/ This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss…

CME credits: 0.50 Valid until: 23-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-practice-changing-strategies-in-community-care-settings-for-patients-with-cllsll-and-mcl/18098/ Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-anemia/26508/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly impro…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/pacritinib-for-myelofibrosis-across-the-cytopenic-spectrum/26507/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can s…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-to-use-prognostic-risk-scoring-and-symptom-burden-assessment-to-tailor-myelofibrosis-treatment/26504/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particu…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/how-and-when-to-manage-ruxolitinib-failure/26505/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly imp…

CME credits: 0.50 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-precision-payloads-exploring-adc-directed-therapies-in-her2-mutant-and-overexpressing-lung-cancer/16609/ Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-discussion-what-jak-inhibitor-should-i-use-in-a-transfusion-dependent-patient-with-mf-with-platelets-50-109l/26512/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhi…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/treatment-options-for-ruxolitinib-intolerance-or-resistance-in-myelofibrosis/26506/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic my…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-transfusion-independence-with-jak-inhibitor-therapy/26509/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, ca…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopen…

CME credits: 1.00 Valid until: 19-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-myelofibrosis-associated-thrombocytopenia/26510/ Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significa…

CME credits: 0.50 Valid until: 18-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancements-in-gu-cancers-key-data-from-aua-2024/24417/ Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who…

CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/managing-adverse-events-associated-with-ici-combinations-in-patients-with-unresectable-hcc/26336/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combination…

CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-supporting-first-line-atezolizumabbevacizumab-in-unresectable-hcc/26331/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the tr…

CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-treatment-choice-the-essential-role-of-shared-decision-making-in-unresectable-hcc/26338/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinati…

CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-unmet-needs-in-the-field-of-unresectable-hcc/26329/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment of unresectable he…

CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-consult-treatment-options-for-an-unresectable-hcc-patient-who-has-esophageal-varices/26335/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations…

CME credits: 1.00 Valid until: 17-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/use-of-ici-combination-regimens-in-patients-with-intermediate-stage-hcc/26333/ This online MinuteCE program provides a comprehensive evaluation of the latest clinical data on first-line immune checkpoint inhibitor (ICI) combinations for the treatment…